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Carcinogenicity of 1,3-Butadiene
by Ronald L. Melnick,' Cynthia C. Shackelford,' and
James Huff'
1,3-Butadiene, ahigh-production volumechemical usedlargely inthemanufacture ofsynthetic rubber, isa multiple
organcarcinogeninratsandmice. IninhalationstudiesconductedinmicebytheNationalToxicology Progran, highrates
ofearlylethallymphomasoccurringatexposurelevelsof625ppmorhigherreducedthedevelopmentandexpressionof
laterdevelopnghtumo atothersites. Useofsurvival-adjusted tumor ratestoaccount forcompeting riskfators provided
aclearerindicationofthedoseresponsesfor1,3-butadiene-nduced neoplasms. Anincreaseinlungtumoninfemalemice
wasobservedatexposureconcentrationsaslowas625ppm,thelowestconcentrationeverusedinalong-termcarcinogenici-
tystudyofthisgas. Humanexposuresto 1,3-butadienebyworkersemployedatfacilitiesthatproducethischemicaland
atfacilities that produce styrene-butadiene rubberhavebeenmeasuredatlevelshigherthanthosethatcausecancerin
animals. Furthermore, epidemiology studies haveconsistently revealed associations betweenoccupational exposure to
1,3-butadiene andexcessmortality duetolymphatic andhematopoietic cancers. In responsetothecarcinogenicity find-
ingsfor1,3-butadieneinanimalsandinhumans,theOccupationalSafetyandHealthAdministationhasproposedlnoering
theoccupationalexposurestandardforthischemicalfrom 1000ppmto2ppm. Futureworkisneededtounderstandthe
mechanisms oftumorinductionby 1,3-butadiene; however, thepursuitofthisresearchshouldnotdelay thereductionof
human exposure tothischemical.
Introduction
1,3-Butadiene (CH2=CH=CH=CH2; CAS no. 106-99-0), a
colorless, noncorrosive, flammable gas (boiling point: -4.4°C),
is produced mainly as a co-product in the steam cracking of
petroleum fractions for the manufacture ofethylene (1). 1,3-
Butadiene is a reactive chemical that can dimerize to 4-vinyl-
cyclohexene or, upon exposure toair, formexplosiveperoxides
(1). The major uses of 1,3-butadiene are in the manufacture of
synthetic rubber (such asstyrene-butadiene rubber orpolybuta-
diene rubber) andofthermoplastic resins. Butadieneelastomers
are used in the manufacture ofrubbertires, footwear, sponges,
hoses, pipes, luggage, packaging, and avariety ofothermolded
products. 1,3-Butadiene is also used as an intermediate in the
production ofother industrial chemicals. Theannualproduction
volume of 1,3-butadiene is approximately 12 billion pounds
worldwide and 3 billion pounds in the United States (2,3).
Based on its high volatility and low water solubility, en-
vironmentally released 1,3-butadienepartitions almostentirely
intotheatmosphere. According to a 1984 surveybythe U.S. En-
vironmental Protection Agency, atmospheric emissions of
1,3-butadiene from facilities that produce or process this
chemical totaledapproximately 10millionpounds per year, with
70% oftheseemissions being attributed toequipment leaks and
30% to process venting (4). 1,3-Butadiene has also been iden-
tified in automobile exhaust, cigarette smoke, and gasoline
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formulations, andsmallamountsarereleasedbytheburningof
plasticsorrubber(5). Lowlevelsof1,3-butadiene(0.5-10ppb)
havebeendetected inambientairinurbanlocationsintheUnited
States; however, in community air at the perimeter of the in-
dustrialcomplex in PbrtNeches, Texas, where 1,3-butadieneand
styrene-butadienerubberareproduced, levelsashighas2 ppm
have beendetected (6).
Approximately 52,00 workers are potentially exposed to
1,3-butadiene inthe United States, asestimated fromdatacom-
piledfromthe National Occupational Exposure Survey (7). In
recent industrial hygiene surveys at four monomer and five
polymermanufacturingplants, occupational exposures to 1,3-
butadiene weregenerallyfoundtobelessthan 10ppm; however,
several maximum 8-hr time-weighted average exposures and
short-term exposures (15-120 min) were between 10 and 150
ppm, and inonecaseas high as 374ppm, inoperations involv-
ing decontamination and maintenance ofprocess equipment,
samplingandanalyzingqualitycontrol samples, andloadingor
unloadingtanktrucksorrailcars(8). Itislikelythatexposures,
especially short-term exposures, during the intensive wartime
start-upofthesynthetic rubberindustry weregreaterthanthose
in following years because ofthe rapid growth ofthe synthetic
rubber industry during World War II and because during the
1940s, 1,3-butadiene was not considered to be hazardous to
humanhealth. Inadditionahightemperature, batchprocess was
used in the early manufacture ofstyrene-butadiene rubber.
1,3-Butadienehaslongbeenconsideredtohavealowandnon-
cumulative toxicity in animals and humans. Early toxicology
studies on 1,3-butadiene indicatedthatthischemicalonlycaused
irritationto mucous membranes, skin, and eyes, ornarcosis at
high concentrations (9). Human volunteers exposed to 2000,MELNICKETAL.
4000, or 8000ppm 1,3-butadiene for6-8 hrexperienced minor
irritationtotheeyesanddifficulty invisual focusing. Thestudies
by Carpenteretal. (9) inthe 1940s formedthebasis forthe 8-hr
time-weighted average workroom exposure concentration stan-
dardof1000ppmsubsequentlypromulgatedbytheU.S. Occupa-
tional SafetyandHealth Administration (OSHA). Resultsofre-
cent carcinogenicity studies of 1,3-butadiene in rats and mice
(10-13) promptedtheAmericanConferenceofGovernmental In-
dustrial Hygienists to lowertheir recommended threshold limit
value (TLV) for 1,3-butadiene in the work environment from
1000 ppm to 10 ppm (14). Meanwhile, OSHA has proposed
lowering theoccupational exposure standard for 1,3-butadiene
to a permissible exposure limit (PEL) of2 ppm with a 15-min
short-termexposure limit(STEL)of10ppm(15). Hearingshave
been held, and a final decision on the proposed change is ex-
pected this year. Proceedings ofan international symposium on
the Toxicology, Carcinogenesis, and Human Health Aspectsof
1,3-Butadienewerepublished in 1990inEnvironmentalHealth
Perspectives (16).
This paperexamines thecarcinogenicitydataof1,3-butadiene
in laboratoryanimals, with specialemphasisontheinfluenceof
competing factors on tumor dose-response relationships,
assessestheimpactofrecentmechanisticdataonourunderstand-
ingofspecies sensitivity to 1,3-butadiene-induced carcinogen-
icity, and compares results of exposure to 1,3-butadiene in
humans to results obtained in animals.
Dose-Response for 1,3-Butadiene-
Induced Carcinogenicity in Mice and
Rats
In the absence of reliable epidemiological data, long-term
studies inlaboratoryanimals arethemostreliable meansofiden-
tifying potential health hazards, especially cancer, in humans.
The carcinogenicity of inhaled 1,3-butadiene was studied in
B6C3F, micebytheNational Toxicology Program(NTP) (10,11)
and inSprague-Dawley ratsbytheInternational InstituteofSyn-
thetic RubberProducers(IISRP) (12,13) todetermine ifthereis
apotential health hazardtohumans. The NTPusually conducts
experiments inFischer344ratsandB6C3F1 mice,andthedura-
tion ofexposure is generally 2 years. Because theIISRP study
was inprogress atthetimeofchemicalselection, theNTPstudy
was performed only in mice.
Inhalation Exposure ofMice to 625 or 1250 ppm
1,3-Butadiene
Twolong-terminhalationexposurestudiesof1,3-butadienein
B6C3F, micehavebeencompletedbytheNTP. Inthefirststudy
(10,11), groups of50 male and 50 female mice were exposed 6
hr/day, 5days/week toaircontaining0(chambercontrol), 625,
or 1250ppm 1,3-butadiene. Theseconcentrationsbracketedthe
OSHA standardof1000ppm. Thisstudy,designedtolastfor 103
weeks, was terminated after 60-61 weeks for humane reasons
becauseofreduced survival atbothexposureconcentrationsdue
tomalignantneoplasms involving multipleorgans inboth sexes.
Malignant lymphomas, which appeared to originate in the
thymusandwereobserved asearlyasweek20, wereconsidered
to be the major cause ofearly deaths.
Incidences ofmalignant lymphomas, hemangiosarcomas of
theheart, andlung neoplasms were increased inboth exposure
groupsofmaleand femalemicecompared with controls. Irons
and co-workers confirmed by cytofluorometric analysis ofcell
surface markersthatthetypeoflymphomacausedby 1,3-buta-
dieneinB6C3F1 miceisaT-cell lymphoma(17,18). Thehigh in-
cidences ofhemangiosarcomas ofthe heart was a particularly
unusual findingbecause theseendothelial cell neoplasms are un-
commoninB6C3F, mice,occurringonly inoneuntreatedmale
andonefemalemouseinthehistoryoftheNTPstudies, andthey
haverarelybeeninducedinlong-termstudies. Earlyinductionand
increased incidencesofforestomachtumorswerealsoobserved
inbothsexesofmice, andincreased incidencesoftumorsofthe
mammary gland, ovary, and liver were observed in females.
Theseresultsdemonstratethat 1,3-butadieneisapotentmulti-
pleorgancarcinogeninmice. However, dose-response relation-
ships were not always clear; for example, the incidences of
hemangiosarcomas oftheheartinmalemicewere0/50forcon-
trols, 16/49 at625 ppm, and 7/49 at 1250 ppm.
Inhalation ExposureofMiceto0-625 ppm
1,3-Butadiene
A second long-term inhalation study of 1,3-butadiene in
B6C3F1 mice, over an expanded range ofexposure concentra-
tions, wasperformedtobettercharacterizedose-responserela-
tionshipsforneoplastic lesionsinducedby thischemical (19,20).
Maleandfemalemicewereexposedto0, 6.25,20,62.5,200, or
625ppmof1,3-butadiene, 6hr/day,5days/weekforupto2years.
Thetopexposurelevel was includedtocoincidewiththelow ex-
posure level in the first study.
Survivalwasreducedformalesandfemalesexposedto20ppm
orhigherconcentrations (Fig. 1), largelyduetothedevelopment
ofcompound-relatedfataltumors. Again, thymiclymphoma, oc-
curring as early as week 23, was the major cause ofdeath for
male and female mice exposed to 625 ppm. The incidence of
lymphoma was also increased in females exposedto200 ppm.
The incidences ofhemangiosarcomas ofthe heart were in-
creased inmalemiceexposedto62.5,200, and625ppm, andin
female mice exposed to 200 and 625 ppm. In addition, one
animal fromthe20-ppmexposuregroupofmalesandone from
the62.5 ppmgroupoffemales wereobservedwiththis uncom-
monendothelial cell tumor; these rare sarcomas are also most
likely due toexposure to 1,3-butadiene.
Interestingly, theincidenceofhemangiosarcomasoftheheart
was greater inmalemiceexposed to200ppm than in those ex-
posedto625ppm. Thisunusualdose-response wasattributed to
theearlyandextensiveinductionoflymphomas at625ppmthat
resultedinasignificantlyreducednumberofmiceatriskforthe
later-developinghemangiosarcomas. Theeffectof"competing
risks" of early occurring lethal thymic lymphomas on the
developmentofhemangiosarcomas oftheheart isevidentfrom
theplotsofthecumulativeincidencesoftheseneoplastic lesions
againstthenumberofweeksonstudyformalemiceexposed to
200 or 625 ppm of 1,3-butadiene (Fig. 2). In the625-ppm ex-
posuregroup, theincidenceofearlylymphomawashigh(70%),
and the incidence of hemangiosarcoma of the heart was low
(5%), butinthe200-ppmexposuregroup, theincidenceofearly
lymphoma was low (4%), and the incidence ofhemangiosar-
coma of the heart (42%) was much higher than that in the
625-ppm exposure group.
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FIGURE 1. Kaplan-Meier survival curves forB6C3F, mice exposed to 1,3-butadiene for 2 years. (A) Male mice; (B) female mice.
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FIGURE 2. Cumulative death-with-tumor rates for lymphomas or hemangiosarcomas ofthe heart versus weeks on study in maleB6C3Fj mice exposed to 200 or
625 ppm 1,3-butadiene.
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FIGURE 3. Cumulative death-with-tumor rates for lymphomas or alveolar-bronchiolar neoplasms versus weeks on study in female B6C3F, mice exposed to 200
or 625 ppm 1,3-butadiene.
The incidences of lung neoplasms in female mice were in-
creased in all exposure groups. Thus, even at 6.25 ppm,
1,3-butadiene is carcinogenic to B6C3F1 mice. Because there
were no exposurelevels atwhich acarcinogenic response was not
induced, itislikelythat exposureconcentrations below6.25 ppm
would also cause cancers in laboratory animals. Extrapolation
ofthedose-response curves to2 ppm,theproposedOSHA stan-
dardfor 1,3-butadiene, results in anestimated2-foldincreasein
lung tumors in female mice. The reduced incidence of lung
neoplasms at625 ppmcomparedwiththeincidence at200 ppm
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Table 1. Sites ofneoplasia and lowest signifcant effect level in male and
female B6C3F, mice in the2-yearinhalation studyof1,3-butadiene.a
Site Male mice Femalemice
Lymphoma +, 200 ppm +, 20 ppm
Heart +,62.5 ppm +,200ppm
Lung +,62.5 ppm +,6.25 ppm
Forestomach +, 200 ppm +, 625 ppm
Liver +,200 ppm +,62.5 ppm
Harderian gland +, 62.5 ppm +, 62.5 ppm
Preputial gland +, 200 ppm NA
Ovary NA +, 62.5 ppm
Mammary gland - +, 62.5 ppm
Brain +(U)
Kidney +(U) ±
Small intestine ±
Zymbal gland + ±
Skin - ±
a(+) Increase relative tocontrols; (±) marginal increase relative tocontrols;
(-) nodifference fromcontrols; NA, notapplicable; U, uncommontumorwith
nonsignificant increased incidence.
was attributed tothehighrateofearlydeathsduetocompeting
risksoflymphoma infemalemiceexposedto625 ppm(Fig. 3).
Foralveolar-bronchiolar neoplasms, thetime-to-tumordetec-
tion wasslightly shorterwithexposureto625ppmthanwithex-
posure to 200 ppm; however, because all the female mice ex-
posedtothisconcentrationof1,3-butadienediedbyweek65, the
final incidence ofthis later-developing and rarely lethal (lung)
tumor was less than thatfor female mice exposedto200ppm.
Neoplasticlesionsoftheforestomach, mammarygland, ovary,
andliver, theotherorgansites identified inthefirststudy, were
again increased in mice exposed to 1,3-butadiene. Inaddition,
the Harderian gland, preputial gland, brain, and kidney were
identified assitesof1,3-butadiene-inducedneoplasia (Table 1).
In unexposed chamber-control female mice, only benign
neoplastic lesions wereobserved inthelung, Harderian gland,
forestomach, and ovary; however, in female mice exposed to
1,3-butadiene, malignant neoplasms were observed in each of
theseorgans(19,20). Inparticular, highincidencesofalveolar-
bronchiolarcarcinomas wereobserved inexposedfemalemice.
Ofthelungtumorsobserved infemalemiceexposedto6.25ppm
1,3-butadiene, 33% werealveolar-bronchiolarcarcinomas. The
greater tendency toward malignancy in mice exposed to 1,3-
butadiene further demonstrates the strong carcinogenic poten-
cy ofthis chemical.
Survival-adjusted Tfmor Rates
The impact of early mortality on the expression of late
developing tumors waslargelyaccounted forbyadjustingfordif-
ferences in survivalpatterns. Survival-adjusted tumorrates for
selected neoplasms are shown in Table 2 for malemice and in
Table3 forfemalemice. Forthetumorincidencesinthesetables,
numerators representthenumberofanimalsbearingthespecific
neoplastic lesion, and denominators represent the adjusted
numberofanimals atrisk. Thelattervaluesweredeterminedby
combining thepartial lifeexperienceforeach oftheanimals in
aparticular exposure group. Thiscombination wasachievedby
calculating the proportion oflifetime tumor riskobserved for
each animal. Animals that survived tothe end ofthe study and
animals thathad the particular tumor in question (early death
animals or animals that lived until the end ofthe study) were
given a weight ofone unit. The weight for an animal that died
Table2. Survival-adjustedratesofselectedneoplasm inmaleB6C3F, mice
inthe2-year inhalation study of1,3-butadiene.'
Exposure concentration, ppm
Site: neoplasm 0 6.25 20 62.5 200 625
Lymphoma 4/44.3 2/46.0 4/40.0 6/39.3 2/27.1 51/52.5
(9.0) (4.3) (10.0) (15.3) (7.4) (97.2)*
Heart: hemangio-
sarcoma
0/43.2 0/45.0 1/38.8 5/37.3 20/31.3 4/7.6
(0.0) (0.0) (2.6) (13.4)* (63.8)* (52.6)*
Lung:alveolar-bron- 21/44.3 23/47.0 19/42.4 31/41.9 35/39.9 3/6.7
chiolar neoplasm (47.4) (48.9) (44.8) (74.0)* (87.7)* (44.8)
aIncidence isgiven as the numberofanimals bearing a neoplastic lesion at a
specific anatomic sitedivided by the adjusted numberofanimals at risk deter-
mined by thepoly-3 survival-adjusted quantal response method ofPortier and
Bailer(21). Survival-adjustedtumorratesaregiveninparentheses, aspercentages.
*Increasedcompared withchamber control (0 ppm),p<0.05.
Table3. Survival-adjustedratesofselectedneoplasmsinfemaleB6C3F, mice
inthe2-yearinhalation studyof1,3-butadiene.a
Exposure concentration, ppm
Site: neoplasm 0 6.25 20 62.5 200 625
Lymphoma 6/46.0 12/44.3 11/40.1 7/35.0 9/22.6 32/37.5
(13.0) (27.1) (27.4) (20.0) (39.8)* (85.3)*
Heart: hemangio- 0/45.4 0/44.1 0/38.8 1/32.7 21/29.3 23/27.6
sarcoma (0.0) (0.0) (0.0) (3.1) (71.6)* (83.2)*
Lung:alveolar-bron- 4/45.5 15/45.5 19/41.0 24/39.4 25/30.8 22/26.8
chiolar neoplasm (8.8) (33.0)* (46.3)* (60.9)* (81.3)* (82.2)*
Ovary:granulosa cell 1/44.4 0/44.1 1/38.2 9/34.2 8/19.5 6/12.9
neoplasm (2.3) (0.0) (2.6) (26.3)* (41.1)* (46.5)*
Mammary gland:
adenocarcinoma 0/45.4 2/44.1 4/39.2 12/36.8 15/26.6 16/24.0
oradenoacanthoma (0.0) (4.5) (10.2)* (32.6)* (56.4)* (66.8)*
alncidence isgiven asthe numberofanimalsbearing a neoplastic lesion at a
specific anatomic sitedivided by theadjusted numberofanimals at risk deter-
mined by thepoly-3 survival-adjusted quantal response method ofPortier and
Bailer(21). Survival-adjustedtumorratesaregiveninparentheses, aspercentages.
*Increased compared with chambercontrol (0 ppm),p<0.05.
beforestudyterminationbutwasfreeofthetumorbeinganalyzed
wasestimatedbycalculatingthefractional survivaltimeonstudy
forthatanimalraisedtothethirdpower. Forexample, ananimal
thatdid nothave ahemangiosarcoma oftheheartanddied due
to lymphoma after about 1/3 of the study (approximately 35
weeks) had (1/3)3 orabout0.04 risk for the development ofthe
hearttumor, ascomparedtoananimal living forthefull study;
however, ifthatanimalhadsurvivedfor2/3ofthestudy(approx-
imately 70weeks), itwouldhavecontributed aweightof(2/3)3
orabout0.30. This survival-adjusted "poly-3 quantalresponse"
methodhasbeendescribedby PortierandBailer (21). Theuse
ofthethirdpowerwasselectedbecausecumulativetumorrates
have been found to occur generally as a third- to fourth-order
functionofageinanimals. Simulationexperiments haveshown
thatthis method isvalid (correctfalse-positive error rate) even
whentheactualvaluesforthepowerareaslowas 1 orashighas
5 (22).
Thesurvival-adjusted tumorratesprovideaclearerindication
ofthedose-responses forneoplasms caused by 1,3-butadiene.
Theapparentdownturn inresponseforhemangiosarcomasofthe
heart and lung neoplasms in male mice exposed to 625 ppm
1,3-butadiene wassubstantially, butnottotally, reversedby ad-
justingforreducedsurvival. Becauseofthelargenumberofearly
deaths due to lymphoma at this exposure level, the adjusted
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number ofanimals atriskfordeveloping heartorlung tumors
was less than 10. Atlowerexposure concentrations, whereear-
ly death due to lymphoma was not a major competing factor,
there was amuch largeradjusted numberofanimals at risk for
theselaterdeveloping tumors. Thus, notunexpectedly, the200
ppm exposure group had the largest number of animals with
heart and lung tumors.
In female mice, the incidence oflymphoma at 625 ppm was
less than that in male mice. Consequently, tumorresponses at
othersiteswerenotasdrastically affectedinfemalesasinmales
atthis exposure level. Exceptfortheovary, theadjustednumber
ofanimals at risk for thelater-developing tumors was approx-
imately 25. As theconcentration of 1,3-butadienewas reduced
from 625 ppmto 6.25 ppm, survival was increased and the ad-
justed number ofanimals at risk increased steadily for each of
these sites. Thehigh adjusted numberofmaleorfemalemiceat
riskforlymphomaat625ppmreflectsthehighincidenceofthis
life-shortening neoplastic lesion.
Fortumorsshowingexposurerelatedeffects, theshapesofthe
dose-response curves were estimated by fitting a modified
Weibull model (23) tothepoly-3 survival-adjustedtumor rates
(20). Forapproximately halfofthetumors evaluated, the dose
response was consistent with a linear model (forestomach
neoplasms inmales andfemales, hemangiosarcomas oftheheart
andpreputialglandtumors inmales, andlymphoma, liver, and
ovarian neoplasms in females). In most instances in which a
departure from linearity was evident, the shape parameter in-
dicated a dose-response curve that was supralinear (concave
downward) in the low dose region (lung and Harderian gland
neoplasms inmalesandfemales, liverneoplasmsinmales, and
mammaryglandtumorsinfemales). Onlyforlymphomainmale
miceandhemangiosarcomaoftheheartinfemalemicewasthere
evidenceofasublinear (concaveupward)dose-responsecurve.
The inhalation studiesconducted at6.25-625 ppm 1,3-buta-
diene provide a better characterization of the concentration-
dependent responsesfor 1,3-butadiene-inducedcancersthandid
thestudiesat625 and 1250ppm. Theobservationofcarcinogen-
icity atallexposurelevelsstudieddemonstratesthatcarcinogenic
responses occur over a200-fold concentration range in mice.
Stop-Exposure Studies
Stop-exposurestudiesweredesignedtoassesstherelationship
betweenexposure levelanddurationofexposureontheoutcome
of1,3-butadiene-induced carcinogenicity andtoconsidertheef-
fect ofvariable worker exposure patterns. These studies were
conducted by exposing groups of 50 male mice to one ofthe
following regimens: a)200ppmfor40weeks; b)625ppmfor 13
weeks; c) 312 ppm for 52 weeks; ord) 625 ppm for 26 weeks
(19,20). Afterthe particular exposures wereterminated, these
groups ofanimals were placed in control chambers for the re-
mainderofthe 104weekstudies. Thetotalexposureto 1,3-buta-
diene (concentration times duration ofexposure) was approx-
imatelyequivalentforthefirsttwogroups(8000ppm-weeksfor
groupsaandb)andprovidedabouthalfthetotalexposuregiven
tothelattertwo groups (16,000ppm-weeks forgroups candd).
The tumor incidence profiles in the stop-exposure groups
showed that lymphomas, hemangiosarcomas ofthe heart, and
tumorsofthelung, forestomach, Harderiangland, andpreputial
gland wereincreasedevenafteronly 13weeksofexposure to625
Table4. Survival-adjusted ratesforlymphomaandhemangioma ofthe
heart in the stop-exposure (SE) groups of male BWC3F, mice exposed to
1,3-butadiene.a
Exposure concentration, ppm
200ppm 625 ppm 312 ppm 625 ppm
SE40 SE 13 SE52 SE26
0 weeks weeks weeks weeks
Site: neoplasm (control) (8,000)b (8,125) (16,224) (16,250)
Lymphoma 9.0 24.1 56.1* 35.0* 87.2*
Heart: hemangio- 0.0 47.1* 30.9* 85.2* 74.5*
sarcoma
aSurvival-adjusted tumor rates, determined by the poly-3 survival-adjusted
quantal response method ofPortierand Bailer(21), are given as percentages.
bTotal exposure expressed asppm-weeks.
*Increased compared with chambercontrol (0 ppm),p<0.05.
ppm of 1,3-butadiene (19,20). It is likely that even shorter ex-
posure durations would also produce a positive carcinogenic
response. Furthermore, atcomparable total exposures, the in-
cidenceoflymphomawasgreaterwithexposuretoahighercon-
centration of1,3-butadiene fora shorttime compared with ex-
posure to alowerconcentration foranextended duration. This
isevidentbycomparingtheadjustedincidenceoflymphomain
the625 ppm 13-weekstop-exposuregroup(56%) withthatinthe
200-ppm40-weekstop-exposuregroup(24%), orbycomparing
the incidence in the 625 ppm 26-week stop-exposure group
(87%) with that in the 312 ppm 52-week stop-exposure group
(35%) (Table 4). Thus, for the development of thymic lym-
phomas, the concentration of 1,3-butadiene is a greater con-
tributingfactorthanisthedurationofexposure. Forothertumor
types, e.g., hemangiosarcomas oftheheart, theratesappeared
tobedependentonthemultipleofexposureconcentrationtimes
thedurationofexposure.
Carcinogenicity of1,3-Butadiene in Rats
In the carcinogenicity study conducted by the IISRP in rats,
groups of 100 animals ofeach sex were exposed to 0, 1000, or
8000 ppm 1,3-butadiene for 6 hr/day, 5 days/week for 2 years
(12,13). Under the conditions ofthis study, 1,3-butadiene was
carcinogenicatmultipleorgansites, asevidencedby increased
incidences and/or dose-response trends for several organ-
specific cancers: pancreaticexocrineneoplasmsandLeydigcell
tumorsofthetestisinmalesanduterinestromalsarcomas, Zym-
balglandcarcinomas, mammaryglandfibroadenomasandcar-
cinomas, andthyroid follicularcell neoplasms infemales. The
increaseinmammaryglandfibroadenomas wasfurtherrelated
to exposure to 1,3-butadiene because the average number of
mammary gland fibroadenomas per rat bearing a mammary
glandtumorwasincreasedinbothexposuregroupscomparedto
controls. Theoccurrenceofuncommonglialcelltumorsofthe
braininexposedmaleratsmayalsohavebeenrelatedtoexposure
to 1,3-butadiene. Theincidencesofbrain,uterine, andmammary
glandtumors were notmuchhigherin the 8000-ppmexposure
group compared to the 1000 ppm exposure group. The nearly
leveldoseresponseforthesetumors wasprobablydueto satura-
tionof1,3-butadienemetabolisminSprague-Dawley rats, which
occursatexposureconcentrationsbetween 1000and2000ppm.
Unlike the response in mice, there were no increases in the
incidences oflymphoma/leukemia, or neoplasms ofthe lung,
heart, forestomach, ovary, liver, Harderiangland, orpreputial
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gland in Sprague-Dawley rats ofeither sex exposed to 1000 or
8000 ppm 1,3-butadiene.
MechanisticStudiesof 1,3-Butadiene
Carcinogenicity and Relevance to
Human Risk
Influence ofMurine Retrovirus
Recentexperimental researchhasbeenaimedatunderstanding
themechanisms oftumorinductionby 1,3-butadiene. Ironsand
co-workers compared the induction ofthymic lymphomas and
the expression ofmurine leukemia retrovirus inB6C3F, mice
and in NIH Swiss mice exposed to 1,3-butadiene for52 weeks
(17,18,24). The Swiss strain ofmousewasusedbecause itdoes
notexpress theecotropicmurineleukemiavirusesexpressedin
B6C3F, mice, and it has a background rate ofnearly zero for
thymic lymphoma. Thefinding that 1 yearofexposure to 1250
ppm 1,3-butadiene caused a 14% incidence ofthymic lympho-
mas inNIH Swissmiceshowsclearlythat 1,3-butadiene induces
this neoplasm independently oftheseactivated retroviruses.
DNA Adducts
Reaction products of guanine with 1,2-epoxy-3-butene or
diepoxybutane weredetectedinliverDNAofB6C3F, mice, but
not in liver DNA ofWistar rats, exposed to 500 ppm ['4C]1,3-
butadiene (25). Future workis needed on DNA adductforma-
tioninthemajortargetsitesof1,3-butadienecarcinogenicity in
B6C3F, miceand in Sprague-Dawley rats attheexposure con-
centrations used inthe2-year studies. Furthermore, the nature
ofthecovalentlybound[' C]1,3-butadiene-derivedradioactivity
to rat liver DNA (26) is yet to be determined.
Metabolism and Pharmacokinetics
Studies onthemetabolismandpharmacokinetics of1,3-buta-
dieneinratsandmicehavebeenundertakentoinvestigateandex-
plain speciesdifferencesinorgan sitespecificity andpotencies
of1,3-butadiene-inducedcarcinogenicity. Biotransformation of
1,3-butadiene is probably an important factor in the car-
cinogenicityofthiscompoundbecausethein vitromutagenici-
tyof1,3-butadiene requiresmetabolicactivation(27), andepox-
ideintermediates of1,3-butadienemetabolismaremutagenicin
Salmonellat)phimurium(28,29)andarecarcinogenicinratsand
mice (30,31).
1,2-Epoxy-3-butene, the first intermediate of 1,3-butadiene
metabolism(32), isformedbyaninducible ratlivermicrosomal
cytochrome P-450monooxygenase (33) (Fig. 4). 1,2-Epoxy-3-
butenehasbeendetectedinexpiredairofSprague-Dawley rats
(33,34) andofB6C3F, mice(35)exposedto 1,3-butadiene, indi-
cating thatthisepoxide intermediate issystemically availablein
exposed animals. Further metabolic transformation of
1,2-epoxy-3-butene involves conjugation with glutathione by
glutathione-S-transferase, oxidationto 1,2:3,4-diepoxybutane,
or hydrolysis by epoxide hydrolase and further oxidation to
3,4-epoxy-1,2-butanediol (36).
Saturation of 1,3-butadiene metabolism in Sprague-Dawley
rats and inB6C3F, mice was reported to occur atatmospheric
concentrations between 1000 and 2000 ppm (37). The rate of
metabolism of1,3-butadiene inmice is about twotimeshigher
CH2=CH-CH=CH2
NADPH
02 microsomes
CH2=CH-CH-CH2
0
1 ,2-Epoxy-3-butene
epoxide NADPH
hydrolase /2 microsomes
0
CH2=CH-CHOH-CH20H CH2-CH-CH-CH2
3-Butene-1 2-diol \ /
NADPH microsomDiepoxybutane 0l2mecrosomes
CH2-CH-CHOH-CH20H
0
3,4-Epoxy- ,2,-butanediol
FIGURE4. Metabolismof 1,3-butadiene.
than that in rats (37,38). This increase is probably due to the
higherrespiratory frequencyofmice(37). Thus, riskassessment
models that account for breathing rate differences between
speciesadjustforthemajorfactorthatdistinguishestheincreased
metabolic rate for 1,3-butadiene in mice compared to rats.
Steady-stateconcentrationsof1,2-epoxy-3-buteneareapprox-
imatelysixtimeshigherinmicethaninratsexposedtothesame
atmosphericconcentrationof1,3-butadiene; however,abouthalf
ofthisdifferenceisattributedtothehigherbreathingrateofmice
comparedtorats(39). Pharmacokineticstudiesof1,3-butadiene
inratsandmicehavenotrevealedspeciesdifferencesofsufficient
magnitude to account forthe different carcinogenic responses
seen in these two species (39). Evidently, other factors are
involvedindistinguishingsite-specificdifferencesinthecarcin-
ogenicityof1,3-butadienebetweenspecies, includinghumans.
More work is needed to understand species differences in 1,3-
butadienepharmacokinetics, metabolicdifferencesandreactivity
ofmetabolicintermediateswithDNAattargetsites,differences
indetoxificationormechanismsofrepair, andtheimpactthese
factors mayhaveon 1,3-butadiene-inducedcarcinogenesis.
EpidemiologyStudies
Associationsbetweenoccupationalexposure to 1,3-butadiene
andincreasedriskofcancerhavebeenevaluatedinretrospective
mortality studiesofworkersemployedatfacilitiesthatproduce
1,3-butadiene (40,41) and at facilities that produce styrene-
butadiene rubber (42-44). Excess mortalities from lymphatic
andhematopoietic cancers among subgroupsofoccupationally
exposed workers in each ofthese studies provides strong evi-
denceforthecarcinogenicityof1,3-butadienetohumans. Rates
ofmortality forlymphosarcomaandreticulumcellsarcomawere
increased by as much as 5.6-fold among workers in a
1,3-butadienemanufacturingplant(40), while5-to6.6-fold in-
creases in mortality from all lymphopoietic cancers and
leukemiawerereportedamongblackworkersintheproduction
areasofstyrene-butadiene-rubberplants(44). Inanestedcase-
controlstudyinwhichthecasesoflymphopoieticcancerswere
comparedtoaninternalpopulationofworkerswhodidnothave
cancer, Matanoski etal. (45)foundthattheexcessleukemias in
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thestyrene-butadiene rubberindustrywereassociatedwithex-
posure to 1,3-butadiene and not to styrene.
Because the epidemiology studies lacked quantitative ex-
posure data, some have considered duration of employment
within broad work job classifications to be an indication of
humanexposure(46,47). Thisrelationshipisprobably notvalid
forthe 1,3-butadieneorstyrene-butadienerubberproductionin-
dustries becausetherehavebeenlargevariabilitiesinexposures
associated withspecific tasks, especiallyduringtherapidgrowth
of the synthetic rubber industry during World War II, and
because processchangesintheproductionof1,3-butadieneand
intheproductionofstyrene-butadienerubberprobablyaffected
workplace exposures overthepast50years. Thus, notsurpris-
ingly, increased mortality forlymphopoietic cancers was most
striking among workers first hired in the 1,3-butadiene and
styrene-butadiene-rubber plantsduringWorldWar11(40-42).
Relevanttothisissuearetheresultsofthe stop-exposure studies
inmice, wheretheexposureconcentrationof1,3-butadienewas
agreatercontributing factortothedevelopmentofthymiclym-
phomas than was theduration ofexposure (19,20).
Conclusions
1,3-Butadiene is a high-production-volume chemical used
largely inthemanufacture ofsynthetic rubber. Theproduction
and use of 1,3-butadiene increased dramatically during World
War II with the development ofthe synthetic rubber industry.
Before the 1980s, 1,3-butadiene was not considered to be par-
ticularly hazardous to human health; therefore, OSHA estab-
lishedapermissiblelimitof1000ppmforoccupational exposure
to this chemical. Results of recent inhalation carcinogenicity
studies have demonstrated clearly that 1,3-butadiene is a
multiple-organ carcinogen in Sprague-Dawley rats and in
B6C3F, mice. Particularly noteworthyinmiceweretheearly oc-
currences andextensivedevelopmentoflymphomas, theinduc-
tion of uncommon hemangiosarcomas of the heart, and the
development ofmalignant lung tumors at exposure concentra-
tions aslowas6.25 ppm. Because6.25 ppmwasthelowestcon-
centration everused inalong-termcarcinogenicity studyofthis
gas, it is likely that lower exposure levels would also cause
cancers in laboratory animals. In addition, multiple organ site
neoplasiawasinduced inmiceafteronly 13 weeksofexposure.
The conclusion that the marginally increased incidences of
hepatocellular neoplasms in male and female mice were
chemically related is strengthenedbythedetectionofactivated
K-ras oncogenes with a specific codon 13 mutation in liver
neoplasmsobtainedfrommiceexposedto 1,3-butadiene(48)in
thecarcinogenicity studies (19,20). ActivatedK-rasoncogenes
have neverbeendetectedinlivertumorsfromuntreatedB6C30F
mice (49). Activated K-ras genes by codon 13 mutations were
also found inlung neoplasms and in someofthelymphomas in-
ducedby exposure to 1,3-butadiene. Inaddition, Wisemanand
Barrett(50) showedthattumor-suppressor genesareinactivated
during 1,3-butadienecarcinogenesis. Thedetectionofactivated
K-ras oncogenes and inactivated tumor suppressor genes in
tumors induced by 1,3-butadiene adds further relevance to the
potential carcinogenicity of 1,3-butadiene in humans because
K-ras is the most commonly detected oncogene in human
cancers, andallele lossesare common in humancancers.
The important issue ofcompeting risks has received little at
tention in theevaluationoflong-termchemical carcinogenesis
experiments. Thestudiesof1,3-butadiene inmiceillustratethe
need to adjust tumor incidence data for survival differences
amonggroupstoprovidereliabledose-responsedatawhencom-
peting risk factors obscure the development and detection of
later-developing neoplastic lesions. Thepoly-3 quantal response
methodwasusedtoadjustforthenumberofanimalsatriskand
thereby provide survival-adjusted tumor rates. For mostofthe
tumors evaluated, the dose responses were consistent with a
linearcurveorsupralinearcurveinthelowdoseregion. Foronly
two tumor responses was there evidence ofa sublinear dose-
response curve.
Tworeactiveepoxides, 1,2-epoxy-3-buteneanddiepoxybutane,
havebeenidentifiedasintermediates inthebiotransformationof
1,3-butadiene in ratsandmice. Metabolism isprobably an im-
portantfactorinthecarcinogenicity of1,3-butadienebecausein
vitro mutagenicity of 1,3-butadiene requires metabolic activa-
tion, whereas these epoxide intermediates are direct-acting
mutagens inbacteriaandarecarcinogens in ratsandmice. The
metabolism of 1,3-butadiene in rats and mice is linear up to
concentrationsofatleast 1000ppm. Pharmacokinetic studieson
1,3-butadieneandon 1,2-epoxy-3-butene haverevealed certain
quantitative differences inmetabolic ratesforthesechemicals in
Sprague-Dawley rats and B6C3F1 mice; however, these dif-
ferences were not of sufficient magnitude to account for the
reporteddifferenttargetsitecarcinogenic responsesinthesetwo
species. Thus,additionalfactors mustbeinvolvedindistinguish-
ing site specificity in the carcinogenicity of 1,3-butadiene
between species.
Epidemiology studiesofworkersemployed intheproduction
of1,3-butadieneorofstyrene-butadienerubberhaveconsistently
revealed associations between occupational exposure to
1,3-butadiene and excess mortality due to lymphatic and
hematopoietic cancers. The excess leukemias in the styrene-
butadiene rubber industry were associated with exposure to
1,3-butadiene and not to styrene. The results from studies in
humans correspond to the increases in lymphoma observed in
mice exposed to 1,3-butadiene.
Basedontheevidenceofcarcinogenicity for 1,3-butadiene in
humansand inexperimental animals, theInternational Agency
forResearchonCancerhasconcludedthat 1,3-butadiene ispro-
bablycarcinogenictohumans(5). Inresponsetothefindingsthat
1,3-butadieneisapotentcarcinogeninanimalsandthathuman
exposure to 1,3-butadieneisassociatedwith excessmortalities
due to lymphatic and hematopoietic cancers, OSHA has pro-
posedtolowertheoccupational standardforthischemical from
1000 ppm to 2 ppm (15). The determination ofthis 500-fold
decrease wasbasedlargelyondatafromtheNTPcarcinogenicity
studies of 1,3-butadiene in mice.
Future research on 1,3-butadiene is needed to elucidate
mechanisms of 1,3-butadiene-induced carcinogenicity and to
morefully assess humanmortality outcomes withbetterquan-
titative estimates ofpastandpresentexposures. The pursuit of
these research objectives should not delay the reduction of
human exposure to this chemical.
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